Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.

Slides:



Advertisements
Similar presentations
International Research
Advertisements

Alexandra Nikolakopoulou Directorate General for Health and Consumers
Chuck Schmal Patent & Trademark Attorney
Prof. Cécile de Terwangne - LAPSI Workshop 7-8 October Re-use and Privacy/Data Protection Cécile de TERWANGNE Professor at the Law Faculty CRID.
Introduction to Article 45 (5) of the CLP Regulation
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
Ato221 - WIPO-UPOV Symp. on IPRs in Plant Biotech., Gva, Article 27.3(b) of the TRIPS Agreement 3.Members may also exclude from patentability:
The European Small Claims Procedure and other EU Instruments: Why is it useful to choose the European Small Claims Procedure? Elena DAlessandro University.
European Commission Enterprise and Industry # European Standardisation: Proposal for a Regulation Presentation to IMCO – 5 October 2011 European Commission.
September 21, 2006 DePaul University, Chicago, IL APLF- DePaul University College of Law 2006 Symposium on Intellectual Property Law.
Environmental Legal TeamEnvironment and Beyond Advanced European Union Law The European Internal Market: Free movement of goods (I) 6 th Lecture,
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
1 Permits and Certificates CITES Secretariat. 2 Overview Permits and certificates Normal procedures.
Taking of evidence within the European Union Council regulation no 1206/2001 on cooperation between the courts of Member States in the taking of evidence.
Industrial Property the Patent system
LATEST DEVELOPMENTS IN BIOTECH PATENTS Carine van den Brink 18 April 2012.
Selected Cases on Patents and Biotechnology WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
Convention on Biological Diversity, Traditional Knowledge and the TRIPS Agreement Yovana Reyes Tagle University of Helsinki.
Patent protection of biotechnology inventions in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Webinar June 27, 2013.
The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
Ethics of Patents in Stem Cell Research
The European legal framework for patentability and regulation of stem cells : focus on Germany, Spain and France Paul Van den Bulck Partner at Ulys Law.
20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Ethics and Patents Gwilym Roberts Partner, Kilburn & Strode Kilburn & Strode LLP | 20 Red Lion Street | London | WC1R 4PJ | United Kingom T: +44.
Aurora Plomer, BA, MA, LLB, PhD Professor of Law & Bioethics Director of SIBLE University of Sheffield
The patentability of human pluripotent embryonic stem cells and stem cell lines Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at the.
Rodolphe Bauer, Frédéric Dedek, Gareth Jenkins, Cristina Margarido
Meanwhile in Europe: HGS Inc v Eli Lilly & co The industrial application test for novel proteins: All in the family? AIPLA Biotech committee meeting 25.
Meyerlustenberger Rechtsanwälte − Attorneys at Lawwww.meyerlustenberger.ch European Patent Law and Litigation Guest Lecture, Health and Intellectual Property.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
W HAT CAN BE PATENTED – AND WHAT DOES THAT MEAN ? András Jókúti Hungarian Intellectual Property Office Ankara, 25 January 2011.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
Patentability of Software and Business Methods A UK and EPO Update Richard Davis Hogarth Chambers May 13, 2011
Patent Eligibility in Europe Colo(u)ring the Gre/ay Areas Ilya Kazi and Andrew Bentham On behalf of International Liaison Committee Supporting logos to.
Biotechnology Assignment 7 Patent Law. Case study 1 –Federal Supreme Court Germany (Bundesgerichshof), 27 March 1969 (Red Dove), IIC, 1970, 136 –Answer.
1 Melbourne Law School University of Melbourne IP trends in the European Union: an overview of recent decisions of the Court of Justice Enrico Bonadio.
Categories of Claims in the Field of CII Edoardo Pastore European Patent Office Torino, October 2011.
UK and European Patent Law - a Review of Recent Developments and Forthcoming Issues Utah IP Summit 18 February 2011 Adrian Bradley.
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
The Eighth Asian Bioethics Conference Biotechnology, Culture, and Human Values in Asia and Beyond Confidentiality and Genetic data: Ethical and Legal Rights.
Seminar Industrial Property Protection Prague, 4 June 2003 Patent Protection in Europe Heidrun Krestel Liaison Officer Member States Co-operation Programmes.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Unitary patent protection in the EU
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
NCCR International Trade NCCR IP9 WORKSHOP 28 th March “Prior Informed Consent in European Patent Law: Overview and Options” - Michelangelo R.P.
© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
Case 428/08 Monsanto v Cefetra e.a THE FUTURE OF BIOTECH PATENT PROTECTION IN EUROPE What every biotech patent practitioner should know John J. Allen.
© J. Straus Patenting of Genes and Life Forms, and the impact of Patenting on Upstream Science Joseph Straus, Munich WIPO Open Forum on the Draft.
CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur TRIPS – Article.
Protection of biotechnology innovations in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Spring Meeting May, 2013.
Patenting Animal Genetic Inventions The Ethics of Patenting Animal Genetic Inventions - NCCR PhD Workshop Michelangelo Temmerman.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
15-16 May 2007Geertrui Van OverwalleEUPACO One size fits all? How unitary is the present European patent system? Geertrui Van Overwalle Centre for Intellectual.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
Funding and patentability of stem cell research in the European Union - A critical legal review of European legislation Dr. Malene Rowlandson, University.
International Intellectual Property Profs. Atik and Manheim Fall, 2006 Biotechnology Patents.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
AIPLA Spring Meeting, Houston Texas
Intellectual Property & Contemporary Issues of Biotechnology Law
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Susy Frankel Victoria University of Wellington New Zealand
Workshop on Erroneously-Filed Elements and Parts
Upcoming changes in the European Patent Office practice on allowing claim amendments in pending patent applications (Article 123(2) EPC) Christof Keussen.
TRIPS Art. 27.3(b) and Agriculture
Presentation transcript:

Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des mandataires agréés près l'Office européen des brevets 1 Patentable Subject-Matter in the area of Biotechnological Inventions Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Agenda 2 Patentability of Plants: – –Legal Basis – –Case Law Further Biotech Subject-Matter epi Involvement Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Patentability of Plants 3 Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Legal Basis 4 Art 53 EPC: Exceptions to patentability European patents shall not be granted in respect of: (a) inventions the commercial exploitation of which would be contrary to "ordre public" or morality; such exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting States; (b) plant or animal varieties or essentially biological processes for the production of plants or animals; this provision shall not apply to microbiological processes or the products thereof; (c) methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body; this provision shall not apply to products, in particular substances or compositions, for use in any of these methods. Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants 5 Decision EBoA, Transgenic Plant/ Novartis II (G 1/98) “A claim wherein specific plant varieties are not individually claimed is not excluded from patentability under Article 53(b) EPC, even though it may embrace plant varieties.” – –Confirmed in Sunflower case (T 1854/07) – –See also Art 4(2) Biotech Directive (98/44/EC) – –and R. 27(b) EPC Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants II 6 EBoA, Tomato I (G 1/08), Broccoli I (G 2/07) – –Essentially biological processes EBoA, Tomato II (G 2/12), Broccoli II (G 2/13) – –Products (i.e. plants) obtained by such processes Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants III 7 Decision EBoA, Tomato I (G 1/08), Broccoli I (G 2/07) 1. A non-microbiological process for the production of plants which contains or consists of the steps of sexually crossing the whole genomes of plants and of subsequently selecting plants is in principle excluded from patentability as being "essentially biological" within the meaning of Article 53(b) EPC. 2. Such a process does not escape the exclusion of Article 53(b) EPC merely because it contains, as a further step or as part of any of the steps of crossing and selection, a step of a technical nature which serves to enable or assist the performance of the steps of sexually crossing the whole genomes of plants or of subsequently selecting plants. Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants IV 8 Decision EBoA, Tomato I (G 1/08), Broccoli I (G 2/07) 3. If, however, such a process contains within the steps of sexually crossing and selecting an additional step of a technical nature, which step by itself introduces a trait into the genome or modifies a trait in the genome of the plant produced, so that the introduction or modification of that trait is not the result of the mixing of the genes of the plants chosen for sexual crossing, then the process is not excluded from patentability under Article 53(b) EPC. 4. In the context of examining whether such a process is excluded from patentability as being "essentially biological" within the meaning of Article 53(b) EPC, it is not relevant whether a step of a technical nature is a new or known measure, whether it is trivial or a fundamental alteration of a known process, whether it does or could occur in nature or whether the essence of the invention lies in it. Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants V 9 Referral EBoA, Tomato II (G 2/12), Broccoli II (G 2/13) “Can the exclusion of essentially biological processes for the production of plants in Article 53(b) EPC have a negative effect on the allowability of a product claim directed to plants or plant material […]?” Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Case Law on Plants VI 10 CFI The Hague, Taste of Nature v. Cresco (8 May 2013) Process exclusion of Art 53(b) EPC does not affect product claims Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Further Biotech Subject-Matter 11 Human embryonic stemm cells: − −Art 6(2)(c) Biotech Directive (98/44/EC) − −Art 53(a), R. 28(c) EPC − −EBoA, Use of embryos/WARF (G 2/06) (25 November 2008) − −CJEU, Brüstle (C-34/10) (18 October 2011) − −BGH, Brüstle (27 November 2012) Nicole van der Laan AIPLA-epi Meeting 13 March 2014

epi Involvement 12 epi Biotech Committee: − −Amicus curiae briefs − −Meetings with EPO directors − −EC Expert Group − −Overview national laws Nicole van der Laan AIPLA-epi Meeting 13 March 2014

Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des mandataires agréés près l'Office européen des brevets Thank you for your attention! 13 Nicole van der Laan, Legal Advisor at epi Nicole van der Laan AIPLA-epi Meeting 13 March 2014